Modulators of eukaryotic initiation factor 2B, compositions and methods

Patent metadata

Field	Value
Publication number	US-11851440-B2
Application number	US-202117531039-A
Country	US
Kind code	B2
Filing date	Nov 19, 2021
Priority date	Aug 9, 2017
Publication date	Dec 26, 2023
Grant date	Dec 26, 2023

Abstract

The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.

First claim

What is claimed is:

1. A method for treating a disease or condition mediated, at least in part, by eukaryotic initiation factor 2B, the method comprising administering to a subject in need thereof an effective amount of a compound, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, selected from the group consisting of:

2. The method of claim 1 , wherein the disease or condition is a neurodegenerative disease.

3. The method of claim 2 , wherein the disease is Alexander's disease, Alper's disease, Alzheimer's disease, Amyotrophic lateral sclerosis, Ataxia telangiectasia, Batten disease (also known as Spielmeyer-Vogt-Sjogren-Batten disease), Bovine spongiform encephalopathy (BSE), Canavan disease, Cockayne syndrome, Corticobasal degeneration, Creutzfeldt-Jakob disease, frontotemporal dementia, Gerstmann-Straussler-Scheinker syndrome, Huntington's disease, HIV-associated dementia, Kennedy's disease, Krabbe's disease, kuru, Lewy body dementia, Machado-Joseph disease (Spinocerebellar ataxia type 3), Multiple sclerosis, Multiple System Atrophy, Narcolepsy, Neuroborreliosis, Parkinson's disease, Pelizaeus-Merzbacher Disease, Pick's disease, Primary lateral sclerosis, Prion diseases, Refsum's disease, Sandhoffs disease, Schilder's disease, Subacute combined degeneration of spinal cord secondary to Pernicious Anaemia, Schizophrenia, Spinocerebellar ataxia (multiple types with varying characteristics), Spinal muscular atrophy, Steele-Richardson-Olszewski disease, vanishing white matter (VWM) disease, insulin resistance, or Tabes dorsalis.

4. The method of claim 2 , wherein the neurodegenerative disease is vanishing white matter (VWM) disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, or dementia.

5. The method of claim 1 comprising administering an effective amount of a compound having the structure:

or a pharmaceutically acceptable salt thereof, to a subject in need thereof.

6. The method of claim 1 comprising administering an effective amount of a compound having the structure:

or a pharmaceutically acceptable salt thereof, to a subject in need thereof.

7. The method of claim 1 comprising administering an effective amount of a compound having the structure:

or a pharmaceutically acceptable salt thereof, to a subject in need thereof.

8. The method of claim 1 comprising administering an effective amount of a compound having the structure:

or a pharmaceutically acceptable salt thereof, to a subject in need thereof.

9. The method of claim 1 comprising administering an effective amount of a compound having the structure:

or a pharmaceutically acceptable salt thereof, to a subject in need thereof.

10. The method of claim 1 comprising administering an effective amount of a compound having the structure:

or a pharmaceutically acceptable salt thereof, to a subject in need thereof.

11. The method of claim 1 comprising administering an effective amount of a compound having the structure:

or a pharmaceutically acceptable salt thereof, to a subject in need thereof.

12. The method of claim 1 comprising administering an effective amount of a compound having the structure:

or a pharmaceutically acceptable salt thereof, to a subject in need thereof.

13. The method of claim 1 comprising administering an effective amount of a compound having the structure:

or a pharmaceutically acceptable salt thereof, to a subject in need thereof.

14. The method of claim 1 comprising administering an effective amount of a compound having the structure:

or a pharmaceutically acceptable salt thereof, to a subject in need thereof.

15. The method of claim 1 comprising administering an effective amount of a compound having the structure:

or a pharmaceutically acceptable salt thereof, to a subject in need thereof.

16. The method of claim 1 comprising administering an effective amount of a compound having the structure:

or a pharmaceutically acceptable salt thereof, to a subject in need thereof.

17. The method of claim 1 comprising administering an effective amount of a compound having the structure:

or a pharmaceutically acceptable salt thereof, to a subject in need thereof.

18. The method of claim 1 comprising administering an effective amount of a compound having the structure:

or a pharmaceutically acceptable salt thereof, to a subject in need thereof.

Assignees

• Denali Therapeutics Inc

Inventors

• Craig Ii Robert A
• De Vicente Fidalgo Javier
• Estrada Anthony A
• Feng Jianwen A
• Fox Brian M
• Hale Christopher R H
• Lexa Katrina W
• Osipov Maksim
• Remarchuk Travis
• Sweeney Zachary K

Classifications

• C07D285/12

  1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles · CPC title

• C07D413/10

  linked by a carbon chain containing aromatic rings · CPC title

• C07D263/20

  attached in position 2 · CPC title

• C07D207/38

  2-Pyrrolones · CPC title

• C07D263/22

  with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms · CPC title